Implementing AMR Surveillance Sustainably in Africa: Insights and Lessons from Ghana, Kenya, and Uganda

Implementing AMR Surveillance Sustainably in Africa: Insights and Lessons from Ghana, Kenya, and Uganda

Blog, Case Studies
Antimicrobial resistance (AMR) is a significant global public health menace. When antimicrobials are ineffective against previously treatable infections, it undermines the ability of health systems around the world to treat even minor infections, resulting in more expensive treatments, and excess mortality and morbidity when infections become untreatable. A recent study on the burden of AMR estimates nearly 5 million deaths associated with bacterial AMR in 2019, with 1.3 million deaths attributable to bacterial AMR 1, suggesting that AMR is at least as large as HIV and malaria. Of all the regions, Sub-Saharan Africa has the highest mortality rate from bacterial AMR at 27.3 deaths per 100,000.1 This high burden is exacerbated by a shortage of trained professionals and limited microbiology laboratory capabilities. In fact, only 1.3% of the 50,000 medical laboratories in…
Read More
Sustainability Planning for Surveillance of Antimicrobial Resistance: Digital Case Studies Series on Antimicrobial Resistance from Kenya, Ghana, and Uganda.

Sustainability Planning for Surveillance of Antimicrobial Resistance: Digital Case Studies Series on Antimicrobial Resistance from Kenya, Ghana, and Uganda.

Case Studies
via Innovations in Healthcare. Antimicrobial resistance (AMR) is a significant global public health menace. The highest mortality rates are seen in Sub-Saharan Africa, where there is a significant shortage of trained professionals and microbiology laboratories for antimicrobial susceptibility testing. To address this, Pfizer Inc., Wellcome Trust, and the Ministries of Health in Ghana, Kenya, Malawi, and Uganda initiated the Surveillance Partnership to Improve Data for Action on AMR (SPIDAAR), a pilot public-private partnership. SPIDAAR aimed to enhance AMR surveillance by training staff in eight hospitals across four countries to conduct diagnostics on 100 isolates per site for five leading pathogens. The isolates were sent to the National Institute for Communicable Diseases (NICD) in South Africa for confirmation, facilitating trend analysis and feedback on culture accuracy. In May 2021, Pfizer engaged Innovations…
Read More